Incyte announces results from Phase 3 trial evaluating retifanlimab in NSCLC

Incyte (INCY) announced results from the Phase 3 POD1UM-304 trial of retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1, in combination with platinum-based chemotherapy for the treatment of adults with previously untreated non-squamous and squamous metastatic non-small cell lung cancer not harboring a driver mutation. These data were featured in a mini oral presentation at the European Society for Medical Oncology Asia Congress 2024, held in Singapore and virtually. The POD1UM-304 trial results show a clinically meaningful and statistically significant improvement over chemotherapy alone. Patients in the retifanlimab and chemotherapy combination treatment group achieved a median overall survival of 18.1 months compared to 13.4 months in the placebo and chemotherapy combination group. The trial also met secondary endpoints, including: Patients who received retifanlimab in combination with chemotherapy had a 2-month improvement in median progression-free survival compared to the placebo and chemotherapy combination group. Overall response rate and duration of response by Blinded Independent Central Review each showed improvement in the retifanlimab and chemotherapy combination treatment group versus the placebo and chemotherapy combination group. Retifanlimab was generally well-tolerated and no new safety issues were identified. The most common treatment-emergent adverse events, in greater than10% of patients in the retifanlimab and chemotherapy combination treatment group, were anemia, decreased appetite and decreased neutrophil count. Chemotherapy administration was not compromised by the addition of retifanlimab.